<DOC>
	<DOCNO>NCT00282971</DOCNO>
	<brief_summary>To assess impact glucose control inhaled insulin patient type 2 diabetes well control 2 oral anti-diabetic agent</brief_summary>
	<brief_title>A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study terminate Nov. 9 , 2007 . This study pursue scientific question complementary wealth data already available Exubera . Pfizer decide cancel new trial decision withdraw Exubera due lack market performance safety reason .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus type 2 Failing two oral antidiabetic agent Asthma , COPD Smoking</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Type 2 diabetes melllitus</keyword>
</DOC>